What is Oncodesign Precision Medicine?
Oncodesign Precision Medicine, established in 1995 and based in Dijon, France, is a biopharmaceutical entity dedicated to the research and development of innovative therapeutic and diagnostic tools. The company offers comprehensive drug discovery services, encompassing in vitro and in vivo pharmacology, metabolism studies, and pharmacokinetics analysis for drug candidates. Furthermore, Oncodesign provides advanced translational biomarker services, biodecontamination, biosafety, and biobanking capabilities. Its strategic focus lies in advancing kinase inhibitor development programs targeting oncology, central nervous system disorders, and inflammatory conditions. The company actively pursues strategic partnerships to accelerate oncology treatment advancements and collaborates on the development of fibrosis drug candidates, positioning itself as a key player in pharmaceutical manufacturing through scientific expertise and technological innovation.
How much funding has Oncodesign Precision Medicine raised?
Oncodesign Precision Medicine has raised a total of $6.3M across 1 funding round:
Other Financing Round
$6.3M
Other Financing Round (2023): $6.3M with participation from Crédit Agricole, Societe Generale, and Caisse d'Epargne
Key Investors in Oncodesign Precision Medicine
Crédit Agricole
Crédit Agricole is a leading French banking and financial services group providing a comprehensive spectrum of financial services, including corporate and investment banking.
Societe Generale
Société Générale is a French multinational financial services company offering a wide range of banking and financial services, including corporate and investment banking.
Caisse d'Epargne
Caisse d'Epargne is a French semi-cooperative bank with a focus on retail and private banking, also participating in broader financial services.
What's next for Oncodesign Precision Medicine?
The substantial enterprise-level capital infusion positions Oncodesign Precision Medicine for accelerated growth and expanded research initiatives. This strategic backing is expected to fuel the advancement of its kinase inhibitor programs in oncology and CNS disorders, as well as its collaborations in fibrosis drug candidate development. The company is poised to leverage this investment to enhance its integrated drug discovery and precision medicine offerings, potentially leading to new therapeutic breakthroughs and solidifying its market presence. Future developments will likely focus on clinical trial progression and the commercialization of its innovative solutions.
See full Oncodesign Precision Medicine company page
